-
1
-
-
78650087357
-
Emerging therapies for the treatment of relapsed or refractory multiple myeloma
-
Dimopoulos MA, San-Miguel JF, Anderson KC. Emerging therapies for the treatment of relapsed or refractory multiple myeloma. Eur J Haematol 2011; 86: 1-15.
-
(2011)
Eur J Haematol
, vol.86
, pp. 1-15
-
-
Dimopoulos, M.A.1
San-Miguel, J.F.2
Anderson, K.C.3
-
3
-
-
79955595041
-
Epidemiology of multiple myeloma
-
Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res 2011; 183: 25-35.
-
(2011)
Recent Results Cancer Res
, vol.183
, pp. 25-35
-
-
Becker, N.1
-
4
-
-
84893800663
-
Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma
-
Fernandez de Larrea C, Jimenez R, Rosinol L, Gine E, Tovar N, Cibeira MT et al. Pattern of relapse and progression after autologous SCT as upfront treatment for multiple myeloma. Bone Marrow Transplant 2013; 49: 223-227.
-
(2013)
Bone Marrow Transplant
, vol.49
, pp. 223-227
-
-
De Fernandez, L.C.1
Jimenez, R.2
Rosinol, L.3
Gine, E.4
Tovar, N.5
Cibeira, M.T.6
-
5
-
-
79955029450
-
Relapsed multiple myeloma
-
Lonial S. Relapsed multiple myeloma. ASH Educ Program Book 2010; 2010: 303-309.
-
(2010)
ASH Educ Program Book
, vol.2010
, pp. 303-309
-
-
Lonial, S.1
-
6
-
-
45449092761
-
The treatment of relapsed and refractory multiple myeloma
-
Richardson P, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Chauhan D et al. The treatment of relapsed and refractory multiple myeloma. Hematol Am Soc Hematol Educ Program 2007; 317-323.
-
(2007)
Hematol Am Soc Hematol Educ Program
, pp. 317-323
-
-
Richardson, P.1
Mitsiades, C.2
Schlossman, R.3
Ghobrial, I.4
Hideshima, T.5
Chauhan, D.6
-
7
-
-
84856719479
-
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
-
Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia 2012; 26: 149-157.
-
(2012)
Leukemia
, vol.26
, pp. 149-157
-
-
Kumar, S.K.1
Lee, J.H.2
Lahuerta, J.J.3
Morgan, G.4
Richardson, P.G.5
Crowley, J.6
-
8
-
-
0026035533
-
Development and characterization of a melphalan-resistant human multiple myeloma cell line
-
Bellamy WT, Dalton WS, Gleason MC, Grogan TM, Trent JM. Development and characterization of a melphalan-resistant human multiple myeloma cell line. Cancer Res 1991; 51: 995-1002.
-
(1991)
Cancer Res
, vol.51
, pp. 995-1002
-
-
Bellamy, W.T.1
Dalton, W.S.2
Gleason, M.C.3
Grogan, T.M.4
Trent, J.M.5
-
9
-
-
0026723149
-
Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies
-
Hall AG, Tilby MJ. Mechanisms of action of, and modes of resistance to, alkylating agents used in the treatment of haematological malignancies. Blood Rev 1992; 6: 163-173.
-
(1992)
Blood Rev
, vol.6
, pp. 163-173
-
-
Hall, A.G.1
Tilby, M.J.2
-
10
-
-
0028229212
-
Up-regulation of gamma-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels
-
Mulcahy RT, Bailey HH, Gipp JJ. Up-regulation of gamma-glutamylcysteine synthetase activity in melphalan-resistant human multiple myeloma cells expressing increased glutathione levels. Cancer Chemother Pharmacol 1994; 34: 67-71.
-
(1994)
Cancer Chemother Pharmacol
, vol.34
, pp. 67-71
-
-
Mulcahy, R.T.1
Bailey, H.H.2
Gipp, J.J.3
-
11
-
-
0028865359
-
Transfection of complementary DNAs for the heavy and light subunits of human gamma-glutamylcysteine synthetase results in an elevation of intracellular glutathione and resistance to melphalan
-
Mulcahy RT, Bailey HH, Gipp JJ. Transfection of complementary DNAs for the heavy and light subunits of human gamma-glutamylcysteine synthetase results in an elevation of intracellular glutathione and resistance to melphalan. Cancer Res 1995; 55: 4771-4775.
-
(1995)
Cancer Res
, vol.55
, pp. 4771-4775
-
-
Mulcahy, R.T.1
Bailey, H.H.2
Gipp, J.J.3
-
12
-
-
4243987802
-
L-S, R-buthionine sulfoximine: Historical development and clinical issues
-
Bailey HH. L-S, R-buthionine sulfoximine: historical development and clinical issues. Chem Biol Interact 1998; 111-112: 239-254.
-
(1998)
Chem Biol Interact
, vol.111-112
, pp. 239-254
-
-
Bailey, H.H.1
-
13
-
-
36348975835
-
Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma
-
Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Bamia C, Pouli A, Baltadakis I et al. Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. Haematologica 2007; 92: 1505-1512.
-
(2007)
Haematologica
, vol.92
, pp. 1505-1512
-
-
Dimopoulos, M.A.1
Souliotis, V.L.2
Anagnostopoulos, A.3
Bamia, C.4
Pouli, A.5
Baltadakis, I.6
-
14
-
-
0018666729
-
Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine)
-
Griffith OW, Meister A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem 1979; 254: 7558-7560.
-
(1979)
J Biol Chem
, vol.254
, pp. 7558-7560
-
-
Griffith, O.W.1
Meister, A.2
-
15
-
-
0020444895
-
Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis
-
Griffith OW. Mechanism of action, metabolism, and toxicity of buthionine sulfoximine and its higher homologs, potent inhibitors of glutathione synthesis. J Biol Chem 1982; 257: 13704-13712.
-
(1982)
J Biol Chem
, vol.257
, pp. 13704-13712
-
-
Griffith, O.W.1
-
16
-
-
9044254931
-
Phase i trial of buthionine sulfoximine in combination with melphalan in patients with cancer
-
O'Dwyer PJ, Hamilton TC, LaCreta FP, Gallo JM, Kilpatrick D, Halbherr T et al. Phase I trial of buthionine sulfoximine in combination with melphalan in patients with cancer. J Clin Oncol 1996; 14: 249-256.
-
(1996)
J Clin Oncol
, vol.14
, pp. 249-256
-
-
O'dwyer, P.J.1
Hamilton, T.C.2
Lacreta, F.P.3
Gallo, J.M.4
Kilpatrick, D.5
Halbherr, T.6
-
17
-
-
0022870696
-
Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells
-
Dorr RT, Liddil JD, Soble MJ. Cytotoxic effects of glutathione synthesis inhibition by L-buthionine-(SR)-sulfoximine on human and murine tumor cells. Invest New Drugs 1986; 4: 305-313.
-
(1986)
Invest New Drugs
, vol.4
, pp. 305-313
-
-
Dorr, R.T.1
Liddil, J.D.2
Soble, M.J.3
-
18
-
-
0028157817
-
Phase i clinical trial of intravenous L-buthionine sulfoximine and melphalan: An attempt at modulation of glutathione
-
Bailey HH, Mulcahy RT, Tutsch KD, Arzoomanian RZ, Alberti D, Tombes MB et al. Phase I clinical trial of intravenous L-buthionine sulfoximine and melphalan: an attempt at modulation of glutathione. J Clin Oncol 1994; 12: 194-205.
-
(1994)
J Clin Oncol
, vol.12
, pp. 194-205
-
-
Bailey, H.H.1
Mulcahy, R.T.2
Tutsch, K.D.3
Arzoomanian, R.Z.4
Alberti, D.5
Tombes, M.B.6
-
19
-
-
0033540268
-
Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis
-
Anderson CP, Tsai JM, Meek WE, Liu RM, Tang Y, Forman HJ et al. Depletion of glutathione by buthionine sulfoxine is cytotoxic for human neuroblastoma cell lines via apoptosis. Exp Cell Res 1999; 246: 183-192.
-
(1999)
Exp Cell Res
, vol.246
, pp. 183-192
-
-
Anderson, C.P.1
Tsai, J.M.2
Meek, W.E.3
Liu, R.M.4
Tang, Y.5
Forman, H.J.6
-
20
-
-
0036671651
-
Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy
-
Anderson CP, Reynolds CP. Synergistic cytotoxicity of buthionine sulfoximine (BSO) and intensive melphalan (L-PAM) for neuroblastoma cell lines established at relapse after myeloablative therapy. Bone Marrow Transplant 2002; 30: 135-140.
-
(2002)
Bone Marrow Transplant
, vol.30
, pp. 135-140
-
-
Anderson, C.P.1
Reynolds, C.P.2
-
21
-
-
0030658870
-
Phase i study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan
-
Bailey HH, Ripple G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C et al. Phase I study of continuous-infusion L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl Cancer Inst 1997; 89: 1789-1796.
-
(1997)
J Natl Cancer Inst
, vol.89
, pp. 1789-1796
-
-
Bailey, H.H.1
Ripple, G.2
Tutsch, K.D.3
Arzoomanian, R.Z.4
Alberti, D.5
Feierabend, C.6
-
22
-
-
0024459864
-
Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice
-
Smith AC, Liao JT, Page JG, Wientjes MG, Grieshaber CK. Pharmacokinetics of buthionine sulfoximine (NSC 326231) and its effect on melphalan-induced toxicity in mice. Cancer Res 1989; 49: 5385-5391.
-
(1989)
Cancer Res
, vol.49
, pp. 5385-5391
-
-
Smith, A.C.1
Liao, J.T.2
Page, J.G.3
Wientjes, M.G.4
Grieshaber, C.K.5
-
23
-
-
35948938057
-
Flow cytometry analysis of single-strand DNA damage in neuroblastoma cell lines using the F7-26 monoclonal antibody
-
Grigoryan RS, Yang B, Keshelava N, Barnhart JR, Reynolds CP. Flow cytometry analysis of single-strand DNA damage in neuroblastoma cell lines using the F7-26 monoclonal antibody. Cytometry A 2007; 71: 951-960.
-
(2007)
Cytometry A
, vol.71
, pp. 951-960
-
-
Grigoryan, R.S.1
Yang, B.2
Keshelava, N.3
Barnhart, J.R.4
Reynolds, C.P.5
-
24
-
-
34548814971
-
Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo
-
Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned TM et al. Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. Blood 2007; 110: 2057-2066.
-
(2007)
Blood
, vol.110
, pp. 2057-2066
-
-
Kang, M.H.1
Kang, Y.H.2
Szymanska, B.3
Wilczynska-Kalak, U.4
Sheard, M.A.5
Harned, T.M.6
-
25
-
-
0033928567
-
Malignant hematopoietic cell lines: In vitro models for the study of multiple myeloma and plasma cell leukemia
-
Drexler HG, Matsuo Y. Malignant hematopoietic cell lines: in vitro models for the study of multiple myeloma and plasma cell leukemia. Leuk Res 2000; 24: 681-703.
-
(2000)
Leuk Res
, vol.24
, pp. 681-703
-
-
Drexler, H.G.1
Matsuo, Y.2
-
27
-
-
0036839144
-
The presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway
-
Chatterjee M, Honemann D, Lentzsch S, Bommert K, Sers C, Herrmann P et al. In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. Blood 2002; 100: 3311-3318.
-
(2002)
Blood
, vol.100
, pp. 3311-3318
-
-
Chatterjee, M.1
Honemann, D.2
Lentzsch, S.3
Bommert, K.4
Sers, C.5
Herrmann, P.6
-
28
-
-
34548689859
-
Characterization of in vitro growth of multiple myeloma cells
-
Zlei M, Egert S, Wider D, Ihorst G, Wasch R, Engelhardt M. Characterization of in vitro growth of multiple myeloma cells. Exp Hematol 2007; 35: 1550-1561.
-
(2007)
Exp Hematol
, vol.35
, pp. 1550-1561
-
-
Zlei, M.1
Egert, S.2
Wider, D.3
Ihorst, G.4
Wasch, R.5
Engelhardt, M.6
-
29
-
-
33644623805
-
DIMSCAN: A microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy
-
Keshelava N, Frgala T, Krejsa J, Kalous O, Reynolds CP. DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. Methods Mol Med 2005; 110: 139-153.
-
(2005)
Methods Mol Med
, vol.110
, pp. 139-153
-
-
Keshelava, N.1
Frgala, T.2
Krejsa, J.3
Kalous, O.4
Reynolds, C.P.5
-
30
-
-
34147135644
-
A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations
-
Frgala T, Kalous O, Proffitt RT, Reynolds CP. A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations. Mol Cancer Ther 2007; 6: 886-897.
-
(2007)
Mol Cancer Ther
, vol.6
, pp. 886-897
-
-
Frgala, T.1
Kalous, O.2
Proffitt, R.T.3
Reynolds, C.P.4
-
31
-
-
78650108430
-
National Cancer Institute pediatric preclinical testing program: Model description for in vitro cytotoxicity testing
-
Kang MH, Smith MA, Morton CL, Keshelava N, Houghton PJ, Reynolds CP. National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing. Pediatr Blood Cancer 2011; 56: 239-249.
-
(2011)
Pediatr Blood Cancer
, vol.56
, pp. 239-249
-
-
Kang, M.H.1
Smith, M.A.2
Morton, C.L.3
Keshelava, N.4
Houghton, P.J.5
Reynolds, C.P.6
-
32
-
-
0031052291
-
Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation
-
Pinguet F, Martel P, Fabbro M, Petit I, Canal P, Culine S et al. Pharmacokinetics of high-dose intravenous melphalan in patients undergoing peripheral blood hematopoietic progenitor-cell transplantation. Anticancer Res 1997; 17: 605-611.
-
(1997)
Anticancer Res
, vol.17
, pp. 605-611
-
-
Pinguet, F.1
Martel, P.2
Fabbro, M.3
Petit, I.4
Canal, P.5
Culine, S.6
-
33
-
-
34547550124
-
Melphalan and its role in the management of patients with multiple myeloma
-
Falco P, Bringhen S, Avonto I, Gay F, Morabito F, Boccadoro M et al. Melphalan and its role in the management of patients with multiple myeloma. Expert Rev Anticancer Ther 2007; 7: 945-957.
-
(2007)
Expert Rev Anticancer Ther
, vol.7
, pp. 945-957
-
-
Falco, P.1
Bringhen, S.2
Avonto, I.3
Gay, F.4
Morabito, F.5
Boccadoro, M.6
-
34
-
-
0028930691
-
HPLC with o-phthalaldehyde precolumn derivatization to measure total, oxidized, and protein-bound glutathione in blood, plasma, and tissue
-
Paroni R, De Vecchi E, Cighetti G, Arcelloni C, Fermo I, Grossi A et al. HPLC with o-phthalaldehyde precolumn derivatization to measure total, oxidized, and protein-bound glutathione in blood, plasma, and tissue. Clin Chem 1995; 41: 448-454.
-
(1995)
Clin Chem
, vol.41
, pp. 448-454
-
-
Paroni, R.1
De Vecchi, E.2
Cighetti, G.3
Arcelloni, C.4
Fermo, I.5
Grossi, A.6
-
35
-
-
0024354304
-
Determination of subcutaneous tumor size in athymic (nude) mice
-
Tomayko MM, Reynolds CP. Determination of subcutaneous tumor size in athymic (nude) mice. Cancer Chemother Pharmacol 1989; 24: 148-154.
-
(1989)
Cancer Chemother Pharmacol
, vol.24
, pp. 148-154
-
-
Tomayko, M.M.1
Reynolds, C.P.2
-
37
-
-
34447249881
-
The pediatric preclinical testing program: Description of models and early testing results
-
Houghton PJ, Morton CL, Tucker C, Payne D, Favours E, Cole C et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 2007; 49: 928-940.
-
(2007)
Pediatr Blood Cancer
, vol.49
, pp. 928-940
-
-
Houghton, P.J.1
Morton, C.L.2
Tucker, C.3
Payne, D.4
Favours, E.5
Cole, C.6
-
38
-
-
80051691845
-
Vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells
-
Chauhan D, Tian Z, Zhou B, Kuhn D, Orlowski R, Raje N et al. In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cells. Clin Cancer Res 2011; 17: 5311-5321.
-
(2011)
Clin Cancer Res
, vol.17
, pp. 5311-5321
-
-
Chauhan, D.1
Tian, Z.2
Zhou, B.3
Kuhn, D.4
Orlowski, R.5
Raje, N.6
-
39
-
-
0027864077
-
Establishment and characterization of new IgD lambda type myeloma cell lines, MOLP-2 and MOLP-3, expressing CD28, CD33 antigens and the IL-6 receptor
-
Matsuo Y, Nakamura S, Adachi T, Tsubota T. Establishment and characterization of new IgD lambda type myeloma cell lines, MOLP-2 and MOLP-3, expressing CD28, CD33 antigens and the IL-6 receptor. Hum Cell 1993; 6: 310-313.
-
(1993)
Hum Cell
, vol.6
, pp. 310-313
-
-
Matsuo, Y.1
Nakamura, S.2
Adachi, T.3
Tsubota, T.4
-
40
-
-
0028302085
-
Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias
-
Corradini P, Inghirami G, Astolfi M, Ladetto M, Voena C, Ballerini P et al. Inactivation of tumor suppressor genes, p53 and Rb1, in plasma cell dyscrasias. Leukemia 1994; 8: 758-767.
-
(1994)
Leukemia
, vol.8
, pp. 758-767
-
-
Corradini, P.1
Inghirami, G.2
Astolfi, M.3
Ladetto, M.4
Voena, C.5
Ballerini, P.6
-
42
-
-
79952122944
-
Cell death assays for drug discovery
-
Kepp O, Galluzzi L, Lipinski M, Yuan J, Kroemer G. Cell death assays for drug discovery. Nat Rev Drug Discov 2011; 10: 221-237.
-
(2011)
Nat Rev Drug Discov
, vol.10
, pp. 221-237
-
-
Kepp, O.1
Galluzzi, L.2
Lipinski, M.3
Yuan, J.4
Kroemer, G.5
-
43
-
-
0035126515
-
Rescue from enhanced alkylator-induced cell death with low molecular weight sulfur-containing chemoprotectants
-
Muldoon LL, Walker-Rosenfeld SL, Hale C, Purcell SE, Bennett LC, Neuwelt EA. Rescue from enhanced alkylator-induced cell death with low molecular weight sulfur-containing chemoprotectants. J Pharmacol Exp Ther 2001; 296: 797-805.
-
(2001)
J Pharmacol Exp Ther
, vol.296
, pp. 797-805
-
-
Muldoon, L.L.1
Walker-Rosenfeld, S.L.2
Hale, C.3
Purcell, S.E.4
Bennett, L.C.5
Neuwelt, E.A.6
-
44
-
-
79961027391
-
Treatment of multiple myeloma
-
Rajkumar SV. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8: 479-491.
-
(2011)
Nat Rev Clin Oncol
, vol.8
, pp. 479-491
-
-
Rajkumar, S.V.1
-
45
-
-
3042775299
-
Clinical course of patients with relapsed multiple myeloma
-
Kumar SK, Therneau TM, Gertz MA, Lacy MQ, Dispenzieri A, Rajkumar SV et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004; 79: 867-874.
-
(2004)
Mayo Clin Proc
, vol.79
, pp. 867-874
-
-
Kumar, S.K.1
Therneau, T.M.2
Gertz, M.A.3
Lacy, M.Q.4
Dispenzieri, A.5
Rajkumar, S.V.6
-
46
-
-
79953125606
-
Treatment of relapsed and refractory multiple myeloma in the era of novel agents
-
van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H et al. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev 2011; 37: 266-283.
-
(2011)
Cancer Treat Rev
, vol.37
, pp. 266-283
-
-
Van De Donk, N.W.1
Lokhorst, H.M.2
Dimopoulos, M.3
Cavo, M.4
Morgan, G.5
Einsele, H.6
-
47
-
-
84946220659
-
Novel approaches to treatment of double-refractory multiple myeloma
-
Lee HC, Shah JJ, Orlowski RZ. Novel approaches to treatment of double-refractory multiple myeloma. Am Soc Clin Oncol Educ Book 2013; 2013: 302-306.
-
(2013)
Am Soc Clin Oncol Educ Book
, vol.2013
, pp. 302-306
-
-
Lee, H.C.1
Shah, J.J.2
Orlowski, R.Z.3
-
48
-
-
0031427398
-
Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines
-
Anderson CP, Tsai J, Chan W, Park CK, Tian L, Lui RM et al. Buthionine sulphoximine alone and in combination with melphalan (L-PAM) is highly cytotoxic for human neuroblastoma cell lines. Eur J Cancer 1997; 33: 2016-2019.
-
(1997)
Eur J Cancer
, vol.33
, pp. 2016-2019
-
-
Anderson, C.P.1
Tsai, J.2
Chan, W.3
Park, C.K.4
Tian, L.5
Lui, R.M.6
-
50
-
-
27244451500
-
Clinical outcomes in t(4;14) multiple myeloma: A chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance
-
Jaksic W, Trudel S, Chang H, Trieu Y, Qi X, Mikhael J et al. Clinical outcomes in t(4;14) multiple myeloma: a chemotherapy-sensitive disease characterized by rapid relapse and alkylating agent resistance. J Clin Oncol 2005; 23: 7069-7073.
-
(2005)
J Clin Oncol
, vol.23
, pp. 7069-7073
-
-
Jaksic, W.1
Trudel, S.2
Chang, H.3
Trieu, Y.4
Qi, X.5
Mikhael, J.6
-
51
-
-
77950421708
-
Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: A prospective, multicenter phase 3 study
-
Palumbo A, Bringhen S, Bruno B, Falcone AP, Liberati AM, Grasso M et al. Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. Blood 2010; 115: 1873-1879.
-
(2010)
Blood
, vol.115
, pp. 1873-1879
-
-
Palumbo, A.1
Bringhen, S.2
Bruno, B.3
Falcone, A.P.4
Liberati, A.M.5
Grasso, M.6
-
52
-
-
0021277282
-
Glutathione-dependent yield and repair of single-strand DNA breaks in irradiated cells
-
Révész L, Edgren M. Glutathione-dependent yield and repair of single-strand DNA breaks in irradiated cells. Br J Cancer Suppl 1984; 6: 55-60.
-
(1984)
Br J Cancer Suppl
, vol.6
, pp. 55-60
-
-
Révész, L.1
Edgren, M.2
-
53
-
-
0023848152
-
Inhibition of radiationinduced DNA-protein cross-link repair by glutathione depletion with L-buthionine sulfoximine
-
Oleinick NL, Xue LY, Friedman LR, Donahue LL, Biaglow JE. Inhibition of radiationinduced DNA-protein cross-link repair by glutathione depletion with L-buthionine sulfoximine. NCI Monogr 1988; 6: 225-229.
-
(1988)
NCI Monogr
, vol.6
, pp. 225-229
-
-
Oleinick, N.L.1
Xue, L.Y.2
Friedman, L.R.3
Donahue, L.L.4
Biaglow, J.E.5
-
54
-
-
22344450423
-
Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome
-
Dimopoulos MA, Souliotis VL, Anagnostopoulos A, Papadimitriou C, Sfikakis PP. Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome. J Clin Oncol 2005; 23: 4381-4389.
-
(2005)
J Clin Oncol
, vol.23
, pp. 4381-4389
-
-
Dimopoulos, M.A.1
Souliotis, V.L.2
Anagnostopoulos, A.3
Papadimitriou, C.4
Sfikakis, P.P.5
-
55
-
-
0028072523
-
DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2
-
Strasser A, Harris AW, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994; 79: 329-339.
-
(1994)
Cell
, vol.79
, pp. 329-339
-
-
Strasser, A.1
Harris, A.W.2
Jacks, T.3
Cory, S.4
-
56
-
-
84882597831
-
Investigation of the antioxidant status in multiple myeloma patients: Effects of therapy
-
Mehdi WA, Zainulabdeen JA, Mehde AA. Investigation of the antioxidant status in multiple myeloma patients: effects of therapy. Asian Pac J Cancer Prev 2013; 14: 3663-3667.
-
(2013)
Asian Pac J Cancer Prev
, vol.14
, pp. 3663-3667
-
-
Mehdi, W.A.1
Zainulabdeen, J.A.2
Mehde, A.A.3
-
57
-
-
79952079462
-
The cytoprotective effect of N-acetyl-L-cysteine against ROS-induced cytotoxicity is independent of its ability to enhance glutathione synthesis
-
Zhang F, Lau SS, Monks TJ. The cytoprotective effect of N-acetyl-L-cysteine against ROS-induced cytotoxicity is independent of its ability to enhance glutathione synthesis. Toxicol Sci 2011; 120: 87-97.
-
(2011)
Toxicol Sci
, vol.120
, pp. 87-97
-
-
Zhang, F.1
Lau, S.S.2
Monks, T.J.3
|